Trisomy 8 in Philadelphia-negative cells during imatinib therapy.
Targeted therapy with imatinib selectively suppresses Philadelphia-positive cells in chronic myeloid leukemia cells, with reappearance of apparently normal hemopoiesis in a considerable number of patients. Recently, clonal abnormalities have been observed in Philadelphia-negative cells during imatinib therapy, the biologic and prognostic significance of which is actually unknown. A case of trisomy 8 occurring in Philadelphia-negative cells, which was treated by bone marrow transplantation, is reported. Chromosomal abnormalities in Philadelphia-negative cells do not seem to herald disease transformation, but the long-term prognosis may be influenced by an increased incidence of myelodysplasia in younger patients.
Bernardeschi
P
P
Oncology Unit and Oncohematology Service, Ospedale S. Giuseppe, Empoli, Italy. p.bernardeschi@usl11.tos.it
Fiorentini
G
G
Rossi
S
S
Dentico
P
P
Simi
P
P
Guidi
S
S
D001549:Benzamides; D016026:Bone Marrow Transplantation; D002869:Chromosome Aberrations / Q000187:drug effects; D002898:Chromosomes, Human, Pair 8; D002999:Clone Cells / Q000473:pathology; D005260:Female; D006801:Humans; D000068877:Imatinib Mesylate; D054438:Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative / Q000188:drug therapy / Q000235:genetics*; D008875:Middle Aged; D010879:Piperazines / Q000009:adverse effects* / Q000627:therapeutic use; D011379:Prognosis; D011743:Pyrimidines / Q000009:adverse effects* / Q000627:therapeutic use; D014314:Trisomy
D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate